GEHCBy Calypso Research8 min read

GE Health Care (GEHC) Q4 2025 Earnings Analysis

Health Care's Rocky Road with $4.7B of Backlog Blues

Key Takeaways

GE Health Care (GEHC) reported Q4 2025 earnings with revenue of $4.7B, representing a -12.1% year-over-year change. The stock moved +4.9% on earnings day.

The bull case: Record backlog, robust service/recurring revenue growth, and a powerful NPI and radiopharmaceutical pipeline (plus IntelliRed and Heartbeat-driven productivity) support accelerating growth and steady margin expansion toward high-teens to 20% over the medium term.

The bear case: China weakness, execution and logistics risk around Vorcado and the NPI wave, and reliance on self-help and pricing in a potentially peaking CapEx cycle could prevent GE HealthCare from achieving its mid-term growth and margin targets.

Financial Highlights

  • Revenue: $4.7B (-12.1% YoY)
  • Gross Profit: $2.5B (54.3% margin, +11.5% YoY)
  • Operating Income: $664M (14.2% margin, -0.9% YoY)
  • Net Income: $184M
  • TTM Revenue: $19.6B

Stock Performance

  • Earnings Day Move: +4.9%
  • Year-to-Date: +1.3%
  • 1-Year Return: -7.4%
  • vs. S&P 500 (since earnings): +9.0%
  • vs. Nasdaq (since earnings): +12.4%

View live GEHC data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from GE Health Care's Q4 2025 earnings call:

Sustainability of Orders Growth, Backlog Quality, and 2026 Revenue Guide (incl. China drag)

Sentiment: Positive

"we really look at three different areas. We look at book-to-bill, which was 1.06 times in the fourth quarter, 1.07 times on a trailing twelve-month basis… We look at the backlog… at a record level… up $2 billion year over year… And then finally, we look at the order growth rate… this gets us to about 4% in the quarter. So we feel pleased with the order backdrop." — Jay Saccaro
"as we start this year… I'll point you back to… the $2 billion increase in total backlog… a strong secured backlog that we have in place… And then, also… we're taking a pragmatic view on China… in our 3% to 4% total company guidance, we're anticipating a decline in China in 2026… maybe there's a scenario we do better than that, but we really wanted to take a cautious approach." — Jay Saccaro

EPS Growth Algorithm, Margin Expansion, and Tariff Mitigation / Heartbeat “Self‑Help”

Sentiment: Positive

"we saw about 50¢ of EPS growth in 2025… when tariffs hit, we took action not only to reduce tariff exposure… but we also did some self-help cost management… our Heartbeat business system help improve our operating margins and reduce waste… As we think about the growth in EPS in 2026… about 30¢ will come from volume growth… about 30¢ will come from cost and productivity initiatives… and then we'll offset that with continued investments in growth." — Jay Saccaro
"we're committed to those midterm targets. Top and bottom, full stop… we realized that the tariffs kind of moved us back a year or two… that's why we really started aggressively last year with moves… that would make a significant difference… our focus on our all our NPIs having higher gross margins than their predicates… is gonna be very important… to be able to deliver on our medium-term profit goals." — Peter Arduini

Vorcado / Flurcato Radiopharmaceutical Ramp and Revenue Potential

Sentiment: Positive

"we really, you know, throttle back how many patients and customers we would bring on until the… on-time delivery is at a 95% rate. And we're roughly in that rate… in the week ended January 23, we delivered 220 doses… we would expect that the doses will go up each of the following weeks… we're on the go slow to go fast… they see the potential… and so we feel very good about where we are at this point in time." — Peter Arduini
"as it relates to Floccato… now we have confidence, and we've started to open up the throttle… we expect weekly dose numbers to grow… we're not gonna give guidance on any specific product at this point… but… based on the progress that we've made over the last couple of months, very pleased with the direction that we're going." — Jay Saccaro

Timing and Magnitude of NPI / RSNA Pipeline Contribution (Photon Counting CT, Omni PET, AVS, MR, etc.)

Sentiment: Positive

"for '26 this year, with all the new products we launched in Q4… until we have those approvals, we can't take an order… once we get that approval, the orders will come in and ramp up rather quickly… there's nine products that probably are the nine biggest ones… in the last decade… all of those have, you know, $100 million plus type capabilities in growth." — Peter Arduini
"we expect those [RSNA] products along with Orcato to help drive one to two points of additional sales growth [in] the medium term… we expect those to have the biggest meaningful contributions in '27, mainly because the order cycle typically is six to nine months… that being said… many of these will have an impact at some point later this year… there's just a lot of buzz about that pipeline." — Peter Arduini

Achievability of Mid‑Term Targets (Mid‑Single‑Digit Revenue, High‑Teens–20% EBIT) and Role of Recurring / Service Revenue

Sentiment: Positive

"we feel good about the midterm targets… this year is a setup. But as we move to next year, you start to see the real benefit from many of the new products… We expect those products along with Orcato to help drive one to two points of additional sales growth… with Heartbeat helping us to deliver higher margin NPIs, to improve productivity, to optimize SG&A, you know, we expect to deliver on our high teens to 20% plus margin targets over the medium term." — Jay Saccaro
"we've talked extensively about our goal to expand recurring revenue… services was a bright spot… we grew sales 6%… we're seeing improved capture rates on our service business… and… utilization… is used heavily, the need for service is there… I think there's a whole set of dynamics that are supporting continued robust growth in our service business." — Jay Saccaro

Bull Case

Record backlog, robust service/recurring revenue growth, and a powerful NPI and radiopharmaceutical pipeline (plus IntelliRed and Heartbeat-driven productivity) support accelerating growth and steady margin expansion toward high-teens to 20% over the medium term.

Bear Case

China weakness, execution and logistics risk around Vorcado and the NPI wave, and reliance on self-help and pricing in a potentially peaking CapEx cycle could prevent GE HealthCare from achieving its mid-term growth and margin targets.

Looking Ahead

With revenue declining -12.1% year-over-year, investors will be watching for signs of a turnaround at GE Health Care, particularly around sustainability of Orders Growth, Backlog Quality, and 2026 Revenue Guide (incl. China drag). With operating margins at 14.2%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was GE Health Care's revenue in Q4 2025?

GE Health Care reported Q4 2025 revenue of $4.7B, representing a -12.1% year-over-year change.

Did GE Health Care beat earnings expectations in Q4 2025?

The stock rose +4.9% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Record backlog, robust service/recurring revenue growth, and a powerful NPI and radiopharmaceutical pipeline (plus IntelliRed and Heartbeat-driven productivity) support accelerating growth and steady margin expansion toward high-teens to 20% over the medium term.

What is the bull case for GEHC stock?

The bull case for GEHC centers on: Record backlog, robust service/recurring revenue growth, and a powerful NPI and radiopharmaceutical pipeline (plus IntelliRed and Heartbeat-driven productivity) support accelerating growth and steady margin expansion toward high-teens to 20% over the medium term.

What is the bear case for GEHC stock?

The bear case for GEHC centers on: China weakness, execution and logistics risk around Vorcado and the NPI wave, and reliance on self-help and pricing in a potentially peaking CapEx cycle could prevent GE HealthCare from achieving its mid-term growth and margin targets.

How has GEHC stock performed since its Q4 2025 earnings?

GEHC moved +4.9% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +9.0% since earnings. Year-to-date, the stock has returned +1.3%.

View all Healthcare Earnings Reports →

Browse all 400+ earnings reports →

Learn More

Analyze GEHC in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for GE Health Care and 400+ other stocks, explore the full platform.

Open GEHC on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.